Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
Permanent URI for this communityhttps://hdl.handle.net/11727/4806
Browse
2 results
Search Results
Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%(2019) Sezer, A.; Gogishvili, M.; Bentsion, D.; Kilickap, S.; Lowczak, A.; Gumus, M.; Gladkow, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Lee, S.; Li, S.; Snodgrass, P.; Navarro, M.; Lowy, I.; Rietschel, P.